Metastatic Solid Tumors Clinical Trials

19 recruiting

Metastatic Solid Tumors Trials at a Glance

76 actively recruiting trials for metastatic solid tumors are listed on ClinicalTrialsFinder across 6 cities in 32 countries. The largest study group is Phase 1 with 69 trials, with the heaviest enrollment activity in Houston, Nashville, and Fairfax. Lead sponsors running metastatic solid tumors studies include Daiichi Sankyo, Innovent Biologics (Suzhou) Co. Ltd., and Hanmi Pharmaceutical Company Limited.

Browse metastatic solid tumors trials by phase

Treatments under study

About Metastatic Solid Tumors Clinical Trials

Looking for clinical trials for Metastatic Solid Tumors? There are currently 19 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Metastatic Solid Tumors trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Metastatic Solid Tumors clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 76 trials

Recruiting
Phase 1

A Phase I Study of SY-9453 in Patients With Advanced Solid Tumors

Advanced or Metastatic Solid Tumors With Homozygous MTAP Deletion
Shouyao Holdings (Beijing) Co. LTD122 enrolled1 locationNCT07469982
Recruiting
Phase 1

A Phase I Study to Investigate the Safety and Tolerability of KGX101 Monotherapy and Combination Therapy With Envafolimab in Advanced or Metastatic Solid Tumor Patients

Advanced or Metastatic Solid Tumors
Kangabio AUSTRALIA LTD PTY57 enrolled3 locationsNCT07260305
Recruiting
Phase 1Phase 2

A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors

Advanced or Metastatic Solid Tumors
Takeda223 enrolled15 locationsNCT07205718
Recruiting
Phase 1

A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors
Avistone Biotechnology Co., Ltd.63 enrolled15 locationsNCT06307795
Recruiting
Phase 1Phase 2

BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)

Urothelial CancerLocally AdvancedSolid Tumor Cancer+1 more
Avenzo Therapeutics, Inc.355 enrolled9 locationsNCT07193511
Recruiting
Phase 1

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

Esophageal CancerGastric CancerCervical Cancer+5 more
Genentech, Inc.450 enrolled41 locationsNCT05581004
Recruiting
Phase 1

Study of XB010 in Subjects With Solid Tumors

Locally Advanced or Metastatic Solid TumorsNSCLC (Non-small Cell Lung Cancer)Esophageal Squamous Cell Cancer+1 more
Exelixis396 enrolled19 locationsNCT06545331
Recruiting
Phase 1

A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors

Advanced/Metastatic Solid Tumors
Antengene Biologics Limited156 enrolled22 locationsNCT05718895
Recruiting
Phase 1

A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors

Advanced/Metastatic Solid Tumors
DualityBio Inc.233 enrolled6 locationsNCT07141706
Recruiting
Phase 1

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

Urothelial CarcinomaBladder CancerAdvanced/Metastatic Solid Tumors+1 more
Pfizer310 enrolled28 locationsNCT07090499
Recruiting
Phase 1

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Metastatic Solid TumorsLocally Advanced Solid TumorsRecurrent Solid Tumors
Genentech, Inc.250 enrolled18 locationsNCT06031441
Recruiting
Phase 1Phase 2

PRISM-NK: Precision-Matched Allogeneic Single- or Dual-Target CAR-NK Cells for Advanced Solid Tumors

Advanced or Metastatic Solid Tumors
Beijing Biotech60 enrolled1 locationNCT07510828
Recruiting
Phase 1Phase 2

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Metastatic Solid TumorsLocally Advanced Solid Tumors
Turning Point Therapeutics, Inc.500 enrolled165 locationsNCT03093116
Recruiting
Phase 1Phase 2

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

Non-small Cell Lung Cancer (NSCLC)Advanced Solid TumorsNSCLC+3 more
Revolution Medicines, Inc.370 enrolled5 locationsNCT07397338
Recruiting
Phase 1Phase 2

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

Breast CancerOvarian CancerEndometrial Cancer+8 more
858 Therapeutics, Inc.120 enrolled14 locationsNCT06395519
Recruiting
Phase 1

A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors

Recurrent or Metastatic Solid Tumors
Daiichi Sankyo76 enrolled26 locationsNCT07015697
Recruiting
Phase 1

A Clinical Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors

Advanced or Metastatic Solid Tumors
Kyowa Kirin Co., Ltd.189 enrolled13 locationsNCT06248411
Recruiting
Phase 1

A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

Advanced Gastric CancerMetastatic Solid TumorsAdvanced Non-squamous Non-small-cell Lung Cancer+4 more
BeiGene514 enrolled17 locationsNCT06585488
Recruiting
Phase 1

Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)

Advanced Solid TumorsMetastatic Solid Tumors
Merck Sharp & Dohme LLC178 enrolled25 locationsNCT05853367
Recruiting
Phase 2

Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Refractory and/or Relapsed Metastatic Solid Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins60 enrolled3 locationsNCT01804634